Trial · NCT03449381
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
NCT03449381, Phase 1, Completed, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors). Trials, record NCT03449381. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03449381
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
- NCT number
- NCT03449381
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 266 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Neoplasms
- Interventions
- BI 907828
- First posted
- 2018-02-28
- Last updated
- 2026-03-31
- Other registries' IDs
- eudract:2017-003210-95
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase Ia- Maximum tolerated dose (MTD) based on number of patients with dose limiting toxicities (DLTs) during first treatment cycle | Up to 28 days | |
| Primary | Phase Ib - Progression-free survival | Up to 24 months | |
| Primary | Phase Ia - Number of patients with DLTs during first treatment cycle (21 days, Arm A; 28 days, Arm B) | Up to 28 days | |
| Primary | Phase Ib - Number of patients with DLTs during the first treatment cycle | Up to 28 days | |
| Secondary | Phase Ia - Cmax: Maximum measured concentration of BI 907828 in plasma | Up to 24 months | |
| Secondary | Phase Ia - AUC0-∞: Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity | Up to 24 months | |
| Secondary | Phase Ib - Objective response | Up to 24 months | |
| Secondary | Phase Ib - Overall survival | Up to 24 months | |
| Secondary | Phase Ib - Number of patients with Grade ≥3 treatment-related adverse events observed during the entire treatment period | Up to 24 months | |
| Secondary | Phase Ib - Cmax: Maximum measured concentration of BI 907828 in plasma | Up to 24 months |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03449381
GET https://conductscience.org/api/trials/v1/NCT03449381/registered